Spinal Muscular Atrophy - Pipeline Insight, 2020

Publisher Name :
Date: 24-Sep-2020
No. of pages: 75
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Spinal Muscular Atrophy - Pipeline Insight, 2020," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Spinal Muscular Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Spinal Muscular Atrophy Understanding

Spinal Muscular Atrophy: Overview

Spinal muscular atrophy (SMA) is a group of inherited disorders characterized by a loss of certain nerve cells in the spinal cord called motor neurons or anterior horn cells. Motor neurons receive the nerve impulses transmitted from the brain to the spinal cord (brainstem) and, in turn, transmit the impulses to the muscle via the peripheral nerves. The loss of motor neurons leads to progressive muscle weakness and muscle wasting (atrophy) in muscles closest to the trunk of the body (proximal muscles) such as the shoulders, hips and back. These muscles are necessary for crawling, walking, sitting up and head control. The more severe types of SMA can affect muscles involved in feeding, swallowing and breathing. SMA is divided into subtypes based on age of onset and maximum function achieved. SMA types 0, 1, 2, 3 and 4 are inherited as autosomal recessive genetic disorders and are associated with abnormalities (mutations) in the SMN1 and SMA2 genes which are located on chromosome 5.

Symptoms

The primary symptom of chromosome 5-related (SMN-related) SMA is weakness of the voluntary muscles. The muscles most affected are those closest to the center of the body, such as those of the shoulders, hips, thighs, and upper back. The lower limbs seem to be affected more than the upper limbs, and deep tendon reflexes are decreased.

Special complications occur if the muscles used for breathing and swallowing are affected, resulting in abnormalities in these functions. If the muscles of the back weaken, spinal curvatures can develop.

Diagnosis

Spinal muscular atrophy (SMA) is sometimes difficult to diagnose, as symptoms can resemble other conditions or medical problems. Doctors usually diagnose SMA after a child has muscle weakness and decreased muscle tone.

If the clinician suspects SMA, they may use the following tests to diagnose the condition:

- Genetic blood tests, which can confirm the diagnosis of SMA

- An electromyography (EMG) test that measures the electrical activity of a muscle or a group of muscles (in some cases)

- A creatine kinase (CPK) test (to distinguish from other types of neuromuscular diseases, if necessary)

Treatment

The management of children with spinal muscular atrophy starts with the diagnosis and classification into 1 of the 5 categories. Health issues specific to spinal muscular atrophy are as follows:

- Pulmonary management: Children with SMA1 can survive beyond 2 years of age when offered tracheostomy or noninvasive respiratory support.

- An intermittent positive-pressure breathing device (mechanical in-exsufflator) has proven effective.

- Nutrition: Bulbar dysfunction is universal in SMA1 patients. Early gastrostomy should be considered as part of the management of such patients. The bulbar dysfunction eventually becomes a serious problem for spinal muscular atrophy II patients and only very late in the course of disease for spinal muscular atrophy III patients.

- In 2017, Spinraza (nusinersen) was FDA-approved as the first drug to treat children and adults with SMA.

- In 2019, the FDA approved Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of children less than two years of age with SMA.

- In 2020, the FDA approved Evrysdi (risdiplam) to treat patients two months of age and older with SMA. Evrysdi is the first orally administered drug approved for the treatment of SMA.

Spinal Muscular Atrophy Emerging Drugs Chapters

This segment of the Spinal Muscular Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spinal Muscular Atrophy Emerging Drugs

- Sodium valproate: Kowa

Sodium valproate is being developed by Kowa for the treatment of Spinal muscular atrophy. It is currently in phase III stage of development.

- SRK-015: Scholar Rock

SRK-015, our most advanced product candidate, is a selective and local inhibitor of the activation of myostatin. Based on existing research on the mechanism of myostatin in muscle growth and strength, Scholar Rock believes the inhibition of the activation of myostatin with SRK-015 may promote a clinically beneficial increase in motor function. Scholar Rock is developing and investigating SRK-015 as a potential treatment to improve muscle strength and motor function in patients with Spinal Muscular Atrophy (SMA).it is currently in phase II stage of development.

- BIIB110: Biogen

BIIB110 is a hybrid activin II receptor (ACTIIR) ligand trap that sequesters both myostatin and activins while sparing the related ligand bone morphogen protein 9 (BMP9). This targeted mechanism of action may result in greater muscle mass, function and improved safety compared to other myostatin inhibition approaches. It is currently in phase I stage of development.

- Research programme: SNA based therapeutics: Exicure

SNA based therapeutics is being developed by Exicure for the treatment of Spinal muscular atrophy. It is currently in preclinical stage of development.

Further product details are provided in the report……..

Spinal Muscular Atrophy: Therapeutic Assessment

This segment of the report provides insights about the different Spinal Muscular Atrophy drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Spinal Muscular Atrophy

There are approx. 40+ key companies which are developing the therapies for Spinal Muscular Atrophy. The companies which have their Spinal Muscular Atrophy drug candidates in the most advanced stage, i.e. phase III include Kowa and others

- Phases

DelveInsight's report covers around 40+ products under different phases of clinical development like

- Late-stage products (Phase II and Phase II/III)

- Mid-stage products (Phase II and Phase II/III)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Spinal Muscular Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Infusion

- Intradermal

- Intramuscular

- Intranasal

- Intravenous

- Oral

- Parenteral

- Subcutaneous

- Topical.

- Molecule Type

Products have been categorized under various Molecule types such as

- Gene therapies

- Small molecule

- Vaccines

- Polymers

- Peptides

- Monoclonal antibodies

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Spinal Muscular Atrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinal Muscular Atrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinal Muscular Atrophy drugs.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Spinal Muscular Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve Spinal Muscular Atrophy.

- In August 2020, Scholar Rock announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for SRK-015 for the treatment of Spinal Muscular Atrophy (SMA).

- In March 2018, Scholar Rock announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead antibody product candidate, SRK-015, for the treatment of spinal muscular atrophy (SMA).

- In July 2018, Biogen announced the acquisition of the muscle enhancement programme from AliveGen, which includes candidate, BIIB 110 (previously known as ALG 801).

Spinal Muscular Atrophy Report Insights

- Spinal Muscular Atrophy Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Spinal Muscular Atrophy Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Spinal Muscular Atrophy drugs?

- How many Spinal Muscular Atrophy drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spinal Muscular Atrophy?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spinal Muscular Atrophy therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Spinal Muscular Atrophy and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Kowa

- Scholar Rock

- Biogen

- Exicure

- AveXis

- Novartis Pharmaceuticals

- Catalyst Pharmaceuticals

- ReveraGen Biopharma

- Translate Bio

Key Products

- Sodium valproate

- SRK-015

- BIIB110

- Leadiant Biosciences

- Vamorolone

- Research programme: SNA based therapeutics

- Amifampridine Phosphate

- Nusinersen

- Onasemnogene

- Branaplam

- Valproic Acid

- Research programme: mRNA therapeutics

Spinal Muscular Atrophy - Pipeline Insight, 2020

Table of Contents

Introduction
Executive Summary
Spinal Muscular Atrophy: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Spinal Muscular Atrophy - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
* Spinal Muscular Atrophy companies' collaborations, Licensing, Acquisition -Deal Value Trends
Spinal Muscular Atrophy Collaboration Deals
* Company-Company Collaborations (Licensing / Partnering) Analysis
* Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
* Comparative Analysis
Sodium valproate: Kowa
* Product Description
* Research and Development
* Product Development Activities
Mid Stage Products (Phase II)
* Comparative Analysis
SRK-015: Scholar Rock
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
* Comparative Analysis
BIIB110: Biogen
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
* Comparative Analysis
Research programme: SNA based therapeutics: Exicure
* Product Description
* Research and Development
* Product Development Activities
Inactive Products
* Comparative Analysis
Spinal Muscular Atrophy Key Companies
Spinal Muscular Atrophy Key Products
Spinal Muscular Atrophy- Unmet Needs
Spinal Muscular Atrophy- Market Drivers and Barriers
Spinal Muscular Atrophy- Future Perspectives and Conclusion
Spinal Muscular Atrophy Analyst Views
Spinal Muscular Atrophy Key Companies
Appendix

List of Tables

Table 1 Total Products for Spinal Muscular Atrophy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Spinal Muscular Atrophy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Lenvatinib Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 130
    According to this study, over the next five years the Lenvatinib market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Lenvatinib business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Lenvatinib market by product type, application, key......
  • Global Levoxyl Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 159
    According to this study, over the next five years the Levoxyl market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Levoxyl business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Levoxyl market by product type, application, key manufact......
  • Global Emergency Contraceptive Pills Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 159
    According to this study, over the next five years the Emergency Contraceptive Pills market will register a 3.2%% CAGR in terms of revenue, the global market size will reach $ 543.7 million by 2025, from $ 478.7 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Emergency Contraceptive Pills business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Emerge......
  • Global Trichomonas Rapid Testing Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 134
    According to this study, over the next five years the Trichomonas Rapid Testing market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Trichomonas Rapid Testing business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Trichomonas Rapid Tes......
  • Global Topical Excipients Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 132
    According to this study, over the next five years the Topical Excipients market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Topical Excipients business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Topical Excipients market by produc......
  • Global Topical Antibiotic Pharmaceuticals Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Topical Antibiotic Pharmaceuticals market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Topical Antibiotic Pharmaceuticals business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Top......
  • Global Tissue-Replacement Products Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 136
    According to this study, over the next five years the Tissue-Replacement Products market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue-Replacement Products business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Tissue-Replacemen......
  • Global Tissue Glue and Bio-adhesive Sealants Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 139
    According to this study, over the next five years the Tissue Glue and Bio-adhesive Sealants market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue Glue and Bio-adhesive Sealants business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities ......
  • Global Tissue Culture Reagents Market Growth 2020-2025
    Published: 27-Oct-2020        Price: US 3660 Onwards        Pages: 135
    According to this study, over the next five years the Tissue Culture Reagents market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Tissue Culture Reagents business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Tissue Culture Reagents m......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs